Blog
RSS FeedPosted by Michael Wonder on 07 Sep 2018
Is US medical care inefficient?
7 September 2018 - Is US medical care inefficient? Many health policy experts maintain it is, whereas others prefer a ...
Posted by Michael Wonder on 05 Sep 2018
Publication of final base-case ICERs (ICURs) by health technology assessment agencies
6 September 2018 - The Department of Health is dragging its heels on this issue. ...
Posted by Michael Wonder on 04 Sep 2018
Why aren't final base-case ICERs published in the PBAC Public Summary Documents?
5 September 2018 - The case for not doing so is now very weak. ...
Posted by Michael Wonder on 04 Sep 2018
Medicaid to introduce value-based drug pricing
4 September 2018 - States have often been an incubator for innovative ideas in health technology pricing and reimbursement. ...
Posted by Michael Wonder on 03 Sep 2018
Medicare-funded cancer genetic tests: a note of caution
3 September 2018 - Clinicians need appropriate education and support in keeping pace with the genomics revolution. ...
Posted by Michael Wonder on 16 Aug 2018
US insurers can peg access to ICER value reviews
16 August 2018 - Latest step in US pricing evolution. ...
Posted by Michael Wonder on 13 Aug 2018
CVS' move to lean on ICER data could mean dramatic shift in drug pricing leverage
13 August 2018 - In an ongoing war over drug prices, leading pharmacy benefit manager CVS Caremark is rolling out ...
Posted by Michael Wonder on 10 Aug 2018
Biosimilars for insulin: a cost-saving alternative?
11 August 2018 - The expiry of patents on an insulin analogue has opened the market to the production of biosimilar ...
Posted by Michael Wonder on 09 Aug 2018
Too-keen medicos cost patients millions
8 August 2018 - Medical procedures likely to have little clinical benefit are still being performed in Australian hospitals, wasting ...
Posted by Michael Wonder on 08 Aug 2018
Comparing the ICERs in medicine reimbursement submissions to NICE and PBAC—does the presence of an explicit threshold affect the ICER proposed?
8 August 2018 - The English NICE and the Australian PBAC require evidence that a new medicine represents value for money ...
Posted by Michael Wonder on 07 Aug 2018
Prices for common cardiovascular drugs in the US are not consistently aligned with value
6 August 2018 - Health care reimbursement agencies in countries other than the US often rely on cost-effectiveness evidence for drug ...
Posted by Michael Wonder on 26 Jul 2018
Meningococcal vaccine rejected as not being "cost-effective"
25 July 2018 - With five cases of meningococccal disease now confirmed in Tasmania, questions are being asked about why the ...
Posted by Michael Wonder on 13 Jul 2018
U.S. ended value-based pricing plan for cancer drug because of doubts it would work
12 July 2018 - The Centers for Medicare and Medicaid Services ended a plan to pay for a $475,000 Novartis ...
Posted by Michael Wonder on 01 Jul 2018
FDA allows off-label health care economic discussions. Is there more to come?
29 June 2018 - The Trump administration has issued final guidance that allows drug companies and device makers to provide ...
Posted by Michael Wonder on 27 Jun 2018
CMS approves state proposal to advance specific Medicaid value-based arrangements with drug makers
27 June 2018 - First-of-its-kind approval for Oklahoma Medicaid will drive value. ...